UK Brain Cancer Review and Faster Orphan Drug Rules Announced

On 14 October 2026, GOV.UK said people with brain cancer should see a quicker route from research to treatment after Prime Minister Andy Burnham and Health Secretary Yvette Cooper met campaigner Archie Goodburn in Downing Street. The announcement sets out four steps: an expert review, a national action plan, a new national brain cancer clinical lead and a faster timetable for reviewing rare-cancer medicine rules. (gov.uk) **What this means for you:** this is not a new cure arriving overnight. It is the government admitting that the path from scientific discovery to an actual treatment offer has been too slow, and promising to speed up that whole chain. (gov.uk)

Archie Goodburn is at the centre of this story because he made the issue impossible to ignore. GOV.UK describes him as a 25-year-old swimmer with inoperable brain cancer who made an emotional plea on BBC Breakfast before meeting ministers in Downing Street. (gov.uk) When you read policy news, it can feel distant. Goodburn’s campaign is a reminder that systems usually move because patients, families and campaigners keep pushing long after the first promise is made. In this case, the government’s own announcement directly links this week’s action to the issues he raised. (gov.uk)

The first step is an immediate expert review led by Professor Anthony Chalmers, chair of the Brain Tumour Group within the UK Collaborative for Cancer Clinical Research, with findings due within three months of 14 October 2026. According to GOV.UK, the review will assess what has changed for patients since the government’s 2018 review of brain tumour research and what is still holding progress back. (gov.uk) After that, ministers say they will produce a national action plan and appoint a new national brain cancer clinical lead. If you have ever seen a government response begin with a review, you will know why these next stages matter: the review is the diagnosis of the system, but the action plan and the named lead are what decide whether anything actually changes. (gov.uk)

If the phrase ‘orphan drugs’ sounds technical, it is worth slowing down here. The Prime Minister has asked the MHRA to finish its review of rules for rare-cancer medicines in two years rather than the three years required by the Rare Cancers Act 2026. The Act says that review must compare the UK’s approach with other countries and judge whether the current rules are effective at encouraging research and development for rare cancer treatments. (gov.uk) Under MHRA guidance, orphan medicines are aimed at life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in the UK, or conditions where normal commercial returns may be too small to justify development. The rules can include incentives such as market exclusivity and some fee refunds, which is why patients and campaigners watch them closely. (gov.uk)

Clinical trials are the other major piece of this plan. Patients, families and charities will help design a push to get more people into trials, while Yvette Cooper is due to host a roundtable with researchers, clinicians and charities to find ways to boost participation. Ministers also say they want the UK to be a better place to run trials, so that patients have more chances to access promising treatments sooner. (gov.uk) If you have ever wondered why a promising treatment does not automatically reach patients, this is part of the answer. Access depends on whether the right people hear about a study, live close enough to take part, meet the rules for joining and are identified quickly enough. The NIHR says 59 brain tumour studies are currently being supported across the country, including 35 clinical trials testing new treatments. (gov.uk)

This announcement sits inside a bigger picture that has been taking shape throughout 2026. The Rare Cancers Act includes duties aimed at improving rare-cancer research and helping potential trial participants be identified and contacted, and the National Cancer Board launched on 21 September 2026 said rare cancers, including brain tumours, would have dedicated expert leads. (legislation.gov.uk) There is also some money and infrastructure already on the table. GOV.UK says the government announced £25 million for the NIHR Brain Tumour Research Consortium in January 2026, and says the Department of Health and Social Care will work with Cancer Research UK next year to bring together global experts and promote the UK as a leading place for brain cancer research. (gov.uk)

The numbers show why families have been so impatient. In the same GOV.UK release, the Department of Health and Social Care says 3,792 people in England died from malignant brain cancer in 2023. That included 278 deaths in people under 40 and 3,514 in people over 40. Cancer Research UK, quoted in the announcement, said it has invested more than £116 million in brain tumour research over the last decade. (gov.uk) **Why this matters:** brain cancer is not only an older person’s issue, and it is not small simply because patient numbers are lower than for some other cancers. For younger adults, the damage lands in the middle of study, work, friendships and plans that should still be opening up, not being cut short. (gov.uk)

There is a reason the response from charities was cautiously hopeful. Brainstrust, Brain Tumour Research, Brain Tumour Support, The Brain Tumour Charity, The Tessa Jowell Foundation and The Tessa Jowell Brain Cancer Mission jointly said the government had listened to the community and recognised the need for urgent change. (gov.uk) But you would also be right to keep one question in view: what changes first, and when? As of 14 October 2026, the clinical lead had not yet been named, the expert review had not yet reported, and the faster orphan-drug timetable still points to years rather than weeks. The real test now is whether today’s promise turns into named leaders, easier trial access and treatments patients can actually reach. (gov.uk)